#FlareTx?thrives because of you - our team. Your dedication, creativity, and hard work illuminate our mission and today, we celebrate and appreciate all that you do! ? #EmployeeAppreciationDay
Flare Therapeutics
生物技术研究
Cambridge ，MA 6,417 位关注者
Trailblazing the path to drugging transcription factors to discover precision medicines for cancer & other disease areas
关于我们
Our team ‘brings it’ every day for one mission: to conquer transcription factors and create cutting-edge medicines. Flare Therapeutics is lighting up new frontiers in biotech by tackling transcription factors – an elusive protein class long considered “undruggable.” Leveraging our proteomic and mass spectrometry platform, proprietary electrophilic compound library and deep expertise, we are unlocking the potential of these critical proteins to address unmet needs in oncology and beyond. Our lead program, FX-909, is a first-in-class investigational orally bioavailable small molecule inhibitor of PPARG, a master regulator of the luminal lineage in advanced urothelial cancer that is currently in a Phase I study. We have also advanced a second program with a differentiated mechanism for prostate cancer entering the Investigational New Drug (IND)-enabling stage, alongside a pipeline of earlier-stage programs targeting transcription factors involved in oncology and other therapeutic areas.
- 网站
-
https://www.flaretx.com
Flare Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Cambridge ，MA
- 类型
- 私人持股
- 创立
- 2021
地点
-
主要
获取路线
US，MA，Cambridge ，02139
Flare Therapeutics员工
动态
-
FlareTx's CEO Doug Manion and?CFO & President Daphne Karydas will be at TD Cowen's 45 Annual Health Conference in Boston on March 5 and Leerink Partners's Global Healthcare Conference in Miami on March 11. Connect with them onsite to learn more about our approach to drugging transcription factors. #biotechnology #flaretx
-
-
The FlareTx team is in San Francisco for #GU25! Today, Evisa Gjini-Bood, PhD, MBA will be presenting data from a poster featuring FX-909, a first-in-class PPARG inhibitor currently being evaluated for advanced urothelial carcinoma in a Phase 1 study, and an assay developed that detects PPARG expression to identify patients most likely to respond to FX-909.? #urothelialcancer #biotechnology #flaretx
-
-
Today, on #WorldCancerDay, we join the global community to raise awareness and honor those affected by cancer. This year's theme, "United by Unique," emphasizes the individual stories of each patient.???? ? At #FlareTx, we are committed to advancing new treatments in precision oncology by targeting transcription factors. Learn more about the importance of people-centered care here:?https://lnkd.in/eTDcNicY ? #oncology #transcriptionfactors #biotech #oneflare
-
-
?? New flares on the team! Help us give a warm welcome to Kelly, Eric, Nastaran, Kelly and Gabrielle, who all recently joined #FlareTx! We look forward to achieving more together as we work on unlocking the potential of transcription factors in the pursuit of new treatments for cancer.? ? Interested in joining us? Explore our current job openings:?https://lnkd.in/ePNXz9sF #bringyourflare?#team?#oneflare?#welcome
-
-
Happy Holidays from all of us at Flare Therapeutics!?? ?? Our team recently gathered to reflect on an incredible year of collaboration, advancement of our discovery programs and lead clinical-stage program FX-909 and a strategic discovery collaboration with Roche.?As we wind down for the winter break, we’re filled with gratitude for the accomplishments we’ve made together and look forward to 2025 in which we #BlazeNewPaths!?
-
-
Our VP of Biochemistry & Chemical Biology Jacob Stuckey, PhD is presenting at American Association for Cancer Research’s Conference on Optimizing Therapeutic Efficacy & Tolerability through Cancer Chemistry today, 12/10 from 2 - 4 pm EST at Plenary Session 4: Drug Design and Optimization - New and emerging targets! Come learn more about our PPARg covalent inverse agonist, FX-909, #FlareTx’s lead candidate for the treatment of bladder cancer. Read more about our science & approach: https://lnkd.in/gRHddDE #biotech #oncology #drugdiscovery
-
-
Our CEO Doug Manion and?CFO & President?Daphne Karydas will be participating in two conferences in December! Catch them at the 7th Annual Evercore ISI HealthCONx Conference on Dec. 4 or at the Piper Sandler Healthcare Conference on Dec. 5. Let’s connect to talk more about how we’re unlocking the therapeutic potential of transcription factors! https://lnkd.in/efVrGeq6 #biotechnology
-
-
Flare Therapeutics will be in San Francisco during #JPM25 in January! If you’d like to learn more about FlareTx’s approach to drugging transcription factors to discover precision medicines for oncology and other therapeutic areas, please reach out to us. We’d love to connect! ? #biotech #TranscriptionFactors #drugdiscovery #oncology #flaretx
-